 "Strides Consumer launches joint pain relief, nicotine replacement products")
Strides Consumer Private Limited (SCPL), a new entrant in the Rs 27,000-crore Indian consumer healthcare product market, on Wednesday formally announced the launch of two maiden products -- Nixit for oral nicotine replacement therapy (NRT) and Jointflex cream for joint pain relief and management in the southern market.
Strides Consumer is owned by InvAscent-backed Indian Life Sciences Fund and Strides Pharma Science Ltd (formerly Strides Shasun) with 74 per cent and 26 per cent shareholding in the company, respectively. It aims to offer high quality, differentiated products in consumer healthcare, based on best of global products with Indian customisation.
Stating that the two products were well received by the consumers in all south Indian metros following the soft launch last year, Strides Consumer chief executive officer, Subodh Marwah, said the firm is currently in the process of building a distributor network across 50 cities in the five southern states this year.
According to Strides Consumer, Nixit is a first-of-its-kind oral NRT that would compete with nicotine patches available in the domestic market, while the topical analgesic cream Jointflex, which consists of Glucosamine and Chondraitin Sulpate compounds, is available for the first time in India. The two products are being produced at a third-party facility owned by Strides Pharma group.
The NRT market is pegged at Rs 156 crore and is expected to reach Rs 600 crore by 2023, while the market for muscle and joint pain relief creams is expected to reach Rs 5,000 crore from the present Rs 3,000 crore in the next five years.
Refusing to share the details of the pipeline of products to be launched by the company, Marwah said the firm was currently focused only on the these two products, though it did not have any immediate sales targets. The consumer health care sector in India is expected to grow two-fold by 2024, he added.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%